NCT05507632View on ClinicalTrials.gov

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 21, 2026

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
COMBINATION_PRODUCT

Donafenib plus Sintilimab in combination with transarterial chemoembolisation

Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT05507632 - Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter